Cite
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
MLA
Garcia, Jacqueline S., et al. “Prophylactic Maintenance with Venetoclax/Azacitidine after Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk MDS and AML.” Blood Advances, vol. 8, no. 4, Feb. 2024, pp. 978–90. EBSCOhost, https://doi.org/10.1182/bloodadvances.2023012120.
APA
Garcia, J. S., Kim, H. T., Murdock, H. M., Ansuinelli, M., Brock, J., Cutler, C. S., Gooptu, M., Ho, V. T., Koreth, J., Nikiforow, S., Romee, R., Shapiro, R., DeAngelo, D. J., Stone, R. M., Bat-Erdene, D., Ryan, J., Contreras, M. E., Fell, G., Letai, A., … Antin, J. H. (2024). Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Advances, 8(4), 978–990. https://doi.org/10.1182/bloodadvances.2023012120
Chicago
Garcia, Jacqueline S, Haesook T Kim, H Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S Cutler, Mahasweta Gooptu, et al. 2024. “Prophylactic Maintenance with Venetoclax/Azacitidine after Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk MDS and AML.” Blood Advances 8 (4): 978–90. doi:10.1182/bloodadvances.2023012120.